Who Owns Xcenda?
Xcenda is owned by Cencora Inc., a publicly traded American healthcare company listed on the NYSE (COR). Cencora operates Xcenda as their strategic consulting and market access brand, providing comprehensive commercialization support and market access services to pharmaceutical companies and healthcare organizations globally.
Parent Company
Cencora Inc.
Founded
1999
Status
Publicly Traded
Headquarters
Conshohocken, Pennsylvania, USA
Who Owns Xcenda?
- Parent Company: Cencora Inc.
- Ownership Type: Wholly owned
- Company Type: Publicly Traded
- Stock Ticker: NYSE: COR
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Xcenda | Cencora Inc. | Wholly owned |
History of Xcenda
- Founded: 1999
- Founders: Xcenda founding team
Xcenda was founded in 1999 as a strategic consulting company focused on helping pharmaceutical companies navigate market access and commercialization challenges. The company developed expertise in market access strategy, reimbursement consulting, and healthcare policy analysis.
Throughout the 2000s and 2010s, Xcenda expanded its service offerings and geographic reach, becoming a leading provider of market access consulting services to pharmaceutical companies globally. The company developed specialized capabilities in evidence generation, health economics, and outcomes research.
Xcenda became known for its ability to help pharmaceutical companies develop comprehensive market access strategies, navigate reimbursement processes, and communicate product value to healthcare stakeholders. The company's expertise in global market access made it a valuable partner for pharmaceutical manufacturers.
In recent years, Xcenda has focused on expanding its commercialization support services, enhancing digital capabilities, and providing integrated consulting solutions. The company has developed specialized services including real-world evidence generation, health economics and outcomes research, and value communication strategies.
Xcenda continues to grow its partnerships with pharmaceutical companies and healthcare organizations, providing strategic consulting services to support successful product launches and market access in key global markets.
About Cencora Inc.
What does Cencora do?
Cencora distributes pharmaceutical products, including brand-name drugs, generic drugs, and specialty medications, to pharmacies, hospitals, physician offices, and other healthcare providers across the United States and internationally. The company also provides manufacturer services, patient support programs, specialty logistics, and veterinary pharmaceutical distribution through its subsidiaries.
Is Cencora publicly traded?
Yes, Cencora, Inc. trades on the New York Stock Exchange under ticker symbol COR. The company has no controlling shareholder, though Walgreens Boots Alliance holds approximately 15% of shares as the largest single investor.
What is Cencora's annual revenue?
In fiscal year 2024 (ended September 30, 2024), Cencora reported revenue of $294.0 billion, a 12.1% increase from the prior fiscal year. The company is one of the largest companies in the United States by revenue.
Why did AmerisourceBergen change its name to Cencora?
AmerisourceBergen changed its name to Cencora in August 2023 to reflect its evolution from a primarily domestic pharmaceutical distributor into a global healthcare solutions organization. The rebranding followed the 2021 acquisition of Alliance Healthcare, which significantly expanded the company's international operations, and was intended to signal the company's broader capabilities beyond traditional drug distribution.
Who is Cencora's CEO?
Robert P. Mauch became President and CEO of Cencora on October 1, 2024, succeeding Steven H. Collis, who had served as CEO since 2011. Collis transitioned to the role of Executive Chairman.
What is Cencora's role in the opioid settlement?
Cencora, along with McKesson and Cardinal Health, reached a $21 billion settlement with U.S. states and local governments in 2022 to resolve claims that the three distributors failed to adequately monitor suspicious opioid orders. Cencora's share of the settlement is approximately $6.1 billion, to be paid over 18 years.
- Founded: 2001
- Headquarters: Conshohocken, Pennsylvania, USA
- Company Type: Publicly Traded
- Stock: NYSE: COR
- Revenue: approximately $293 billion (FY2024, year ended September 2024)
- Employees: Approximately 47,000
Where Is Xcenda Made / Based?
- Headquarters: Conshohocken, Pennsylvania, USA
- Manufacturing / Operations: United States, Europe, Canada
Xcenda Sustainability & Ethics
Xcenda operates under Cencora's comprehensive environmental and social governance framework, with specific focus on sustainable healthcare consulting practices and ethical market access strategies.
Environmental Initiatives: Xcenda participates in Cencora's environmental sustainability programs, including Scope 1 and 2 emissions reduction targets. In fiscal 2024, Cencora completed solar photovoltaics installations and implemented energy efficiency measures across its facilities. Xcenda contributes to these goals through optimization programs for consulting operations and investments in sustainable business practices.
Healthcare Access and Equity: As a market access consulting firm, Xcenda's core mission involves improving healthcare access and equity through strategic consulting services. The company helps pharmaceutical companies develop market access strategies that balance commercial objectives with patient access considerations, supporting broader healthcare equity goals.
Environmental Responsibility: Xcenda contributes to Cencora's environmental sustainability initiatives through responsible business operations, including energy-efficient office practices, reduced paper usage through digital consulting tools, and sustainable business travel policies. The company supports Cencora's broader environmental goals while maintaining its focus on consulting excellence.
Healthcare Access Equity: Xcenda's market access strategies emphasize equitable healthcare access, helping pharmaceutical companies develop pricing and reimbursement strategies that balance commercial viability with patient accessibility. The company works to ensure that innovative treatments reach diverse patient populations while supporting healthcare system sustainability.
Professional Ethics and Compliance: Xcenda maintains strict compliance with healthcare industry regulations and professional standards, including anti-kickback statutes, Sunshine Act requirements, and pharmaceutical industry codes of conduct. The company's consulting services ensure that all market access strategies comply with regulatory requirements.
Employee Well-being and Development: Xcenda invests in employee development and well-being programs, supporting professional growth in healthcare consulting while maintaining work-life balance. The company's commitment to employee welfare extends to mental health support, professional training, and career advancement opportunities.
Community Engagement: Through Cencora's community engagement programs, Xcenda participates in healthcare initiatives that support underserved communities and improve healthcare access. The company's consulting expertise contributes to broader healthcare improvement efforts beyond commercial client services.
Responsible Market Access: Xcenda's core consulting services emphasize responsible market access strategies that consider healthcare system sustainability, payer constraints, and patient needs. The company helps pharmaceutical partners develop market access approaches that balance innovation with affordability and accessibility.
Awards & Recognition
Xcenda has received recognition within the healthcare consulting and pharmaceutical industries for its expertise in market access strategy, commercialization support, and health economics outcomes research. While the brand operates primarily as a B2B consulting service, its contributions to pharmaceutical commercialization have been acknowledged by industry organizations and client partners.
Healthcare Consulting Leadership: Xcenda is consistently recognized as a leading provider of market access and commercialization consulting services in the pharmaceutical industry. The company's expertise in navigating complex healthcare reimbursement landscapes has been acknowledged by pharmaceutical companies and healthcare organizations.
Market Access Innovation Recognition: Xcenda's innovative approaches to market access strategy development have been recognized within the healthcare consulting industry. The company's ability to translate clinical evidence into compelling value propositions for payers and healthcare providers has been noted as demonstrating best practices in pharmaceutical commercialization.
Client Success Recognition: Many of Xcenda's pharmaceutical clients have achieved successful product launches and market access outcomes, reflecting the company's effectiveness in strategic consulting. While these successes represent client achievements rather than formal awards, they demonstrate Xcenda's impact on pharmaceutical commercialization.
Professional Development: Xcenda maintains a fellowship program that develops talent in healthcare consulting, with graduates going on to leadership positions in the pharmaceutical and healthcare industries. The program is recognized for its comprehensive training in market access and commercialization.
Industry Partnerships: Xcenda collaborates with professional organizations such as the Academy of Managed Care Pharmacy (AMCP) and other healthcare industry groups, contributing to educational initiatives and industry standards development.
Thought Leadership Recognition: Xcenda's insights and research publications on healthcare policy, market access trends, and reimbursement strategies are frequently cited in industry publications and referenced by healthcare stakeholders. This thought leadership position represents recognition of the company's expertise and analytical capabilities.
Innovation in Healthcare Consulting: Xcenda has been recognized for developing innovative approaches to market access challenges, including real-world evidence generation, value communication strategies, and digital health integration. These innovative methodologies have influenced industry practices and consulting approaches.
Professional Expertise Acknowledgment: Xcenda's team of healthcare consultants, including experts in health economics, outcomes research, and policy analysis, are recognized for their deep industry knowledge and ability to navigate complex healthcare environments. This professional expertise represents a competitive advantage and form of industry recognition.
Integration Success Recognition: Xcenda's successful operation within Cencora's broader healthcare services portfolio demonstrates effective integration and strategic alignment. The company's ability to maintain consulting independence while leveraging Cencora's resources represents successful business model execution.
Xcenda Recalls & Controversies
Xcenda has maintained a strong operational record with no major consulting scandals or significant controversies directly involving the company. However, the healthcare consulting industry faces ongoing challenges that affect Xcenda's operations and client relationships.
No Direct Consulting Scandals: Xcenda has not been involved in any major consulting scandals or ethical breaches since its founding in 1999. The company's focus on healthcare consulting rather than direct patient care reduces its exposure to certain types of healthcare controversies, though it must maintain high ethical standards in all client work.
Healthcare Industry Regulatory Challenges: The healthcare consulting industry operates under increasingly complex regulatory requirements across multiple jurisdictions. Xcenda must navigate differing requirements from FDA, EMA, and other international health authorities, creating ongoing compliance challenges for its consulting services.
Pharmaceutical Industry Cost Pressures: Xcenda's clients face ongoing pressure from healthcare cost containment efforts, which can affect consulting budgets and project scopes. The emphasis on reducing healthcare costs creates challenges for market access strategies and value demonstration consulting.
Data Privacy and Security Concerns: As a consulting firm handling sensitive healthcare data and proprietary pharmaceutical information, Xcenda faces ongoing challenges related to data privacy, cybersecurity, and compliance with healthcare data protection regulations including HIPAA and GDPR.
Conflicts of Interest Management: Healthcare consulting firms must carefully manage potential conflicts of interest when working with multiple pharmaceutical companies and healthcare stakeholders. Xcenda maintains strict policies to avoid conflicts while serving diverse client portfolios in competitive markets.
Healthcare Policy Uncertainty: The evolving healthcare policy landscape, including changes in reimbursement systems, regulatory requirements, and market access frameworks, creates ongoing challenges for Xcenda's consulting services and strategic recommendations to clients.
Market Access Complexity: Increasing complexity in healthcare market access, including growing requirements for health economics evidence and value demonstration, creates challenges for consulting firms. Xcenda must continuously adapt its methodologies to meet evolving payer expectations and regulatory standards.
Competition and Consolidation: The healthcare consulting industry faces consolidation pressure, with larger firms acquiring specialized consultants. Xcenda operates within Cencora's diversified healthcare services portfolio, which provides stability but also requires strategic alignment with broader corporate objectives.
Brands Owned by Cencora Inc.
- AmerisourceBergen - Legacy brand name of Cencora Inc., one of the largest pharmaceutical distributor...
- GoodRx - American healthcare technology platform providing prescription drug price compar...
- Lash Group - Patient support services company providing pharmaceutical patient assistance pro...
- MWI Animal Health - Animal health pharmaceutical and supply distributor providing veterinary medicat...
- OneOncology - Physician-led community oncology platform providing practice management, clinica...
- Retina Consultants of America - Leading retina specialist management services organization providing practice ma...
- World Courier - Global specialty logistics and transportation company specializing in time-criti...
Xcenda Ownership: Pros & Cons
Advantages
- +Deep expertise in market access and commercialization strategy
- +Global reach with operations across North America and Europe
- +Integration with Cencora's pharmaceutical distribution expertise
- +Comprehensive consulting services covering evidence generation and health economics
- +Strong relationships with pharmaceutical companies and healthcare stakeholders
- +Access to real-world data and healthcare insights
Considerations
- -Dependency on Cencora's corporate policies and strategic direction
- -Competition from other healthcare consulting firms
- -Regulatory compliance requirements for healthcare consulting services
- -Pressure on consulting margins from healthcare cost containment efforts
- -Limited flexibility in certain operational decisions due to corporate structure
- -Evolving healthcare policy and reimbursement landscape
Frequently Asked Questions About Xcenda
Sources & Further Reading
- Xcenda Official Website
- Xcenda Insights and Research
- Cencora Corporate Responsibility
- Cencora Environmental Sustainability
- Cencora Corporate Responsibility Reports
- Cencora 2025 CDP Climate Submission
- Xcenda LinkedIn Company Page
- Healthcare Consulting Industry Analysis — PitchBook Company Profile
- Healthcare Policy and Regulatory Resources — Industry publications and analysis
- Health Economics and Outcomes Research — Professional journals and publications
- Market Access Strategy Resources — Healthcare industry publications
Where to Buy
Disclosure: We may earn commission from purchasesCompetitors to Xcenda
No direct competitors found in the same category. This could be because Xcendaoperates in a unique market segment or we're still building our competitor database.
Cencora Inc. Stock Information
Jobs at Cencora Inc.
Latest News About Xcenda
Related Articles About Xcenda
View more articlesMonthly IPO Roundup: July 2026 — June's Biggest Listings
June 2026 was the most historic IPO month in market history: SpaceX priced at $135 per share on June 12, raising $75 billion in the largest IPO ever. Quantinuum raised $1.68B, INNIO priced a $2.8B deal, and Bending Spoons filed for a $20B Nasdaq listing. Full recap.
Monthly M&A Roundup: June 2026 Brand Ownership Changes
June 2026's biggest brand ownership moves: Berkshire Hathaway agreed to buy Taylor Morrison for $6.8B, GSK struck a $10.6B deal for Nuvalent, CRH acquired Arcosa for $8.5B, and Qualcomm agreed to buy AI startup Modular for $3.92B. Full breakdown of every major deal.
A Complete Guide to LVMH Brands: What Does the Luxury Giant Own?
LVMH owns 75 luxury maisons including Louis Vuitton, Dior, Tiffany, Guerlain, and Sephora. Here is the complete brand list by division, with acquisition dates and what each brand does.
People Also Searched
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.

Accutane
Prescription isotretinoin brand developed by Roche and approved by the FDA in 1982 for severe nodular acne. Roche discontinued the brand name in the United States in 2009; the drug continues as Roaccutane in international markets.

Activase
Activase (alteplase) is a prescription thrombolytic medication manufactured by Genentech, a wholly-owned subsidiary of Roche. Used to treat acute ischemic stroke, heart attack, and pulmonary embolism.

Acuvue
Acuvue is the world's leading contact lens brand, owned by Johnson & Johnson Vision Care, a division of Johnson & Johnson. The brand covers daily, weekly, and monthly disposable soft contact lenses sold in more than 100 countries.